Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TALZENNA safely and effectively. See full prescribing information for TALZENNA. TALZENNA® (talazoparib) capsules, for oral use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA [see Dosage and Administration (2.1)]. TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see Dosage and Administration (2.3)].
- generic_name
- talazoparib
- product_names
- talazoparib
- ndc
- 0069-0296, 0069-1195, 0069-1501, 0069-1751, 0069-1031, 0069-1235, 0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en